Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M

Nautilus Biotechnology, Inc.

2024-Q3 EPS reported -$0.42

Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.
Operating expenses $19.1M, flat YoY; personnel cost increase offset by incentive accrual reduction.
Cash, equivalents, and investments totaled $221.2M as of September 30, 2024.
CEO notes positive researcher feedback for single-molecule proteome platform, no revenue reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.